Exelixis
EXEL
#1700
Rank
$9.89 B
Marketcap
$34.66
Share price
0.03%
Change (1 day)
65.60%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024 (TTM): $2.08 Billion USD

According to Exelixis's latest financial reports the company's current revenue (TTM ) is $2.08 Billion USD. In 2023 the company made a revenue of $1.83 Billion USD an increase over the revenue in the year 2022 that were of $1.61 Billion USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) $2.08 B13.74%
2023 $1.83 B13.6%
2022 $1.61 B12.27%
2021 $1.43 B45.31%
2020 $0.98 B2.04%
2019 $0.96 B13.35%
2018 $0.85 B88.7%
2017 $0.45 B136.34%
2016 $0.19 B415.05%
2015 $37.17 M48.03%
2014 $25.11 M-19.87%
2013 $31.33 M-33.96%
2012 $47.45 M-83.62%
2011 $0.28 B56.52%
2010 $0.18 B21.93%
2009 $0.15 B28.76%
2008 $0.11 B3.87%
2007 $0.11 B15%
2006 $98.67 M29.9%
2005 $75.96 M43.71%
2004 $52.85 M2.56%
2003 $51.54 M16.29%
2002 $44.32 M8.09%
2001 $41 M65.62%
2000 $24.75 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
$40.25 B 1,833.74%๐Ÿ‡ฌ๐Ÿ‡ง UK
$53.50 B 2,470.48%๐Ÿ‡ซ๐Ÿ‡ท France
$62.47 B 2,901.49%๐Ÿ‡บ๐Ÿ‡ธ USA
$47.43 B 2,178.78%๐Ÿ‡บ๐Ÿ‡ธ USA
$32.53 B 1,462.93%๐Ÿ‡บ๐Ÿ‡ธ USA
$87.69 B 4,112.92%๐Ÿ‡บ๐Ÿ‡ธ USA
$55.64 B 2,573.04%๐Ÿ‡บ๐Ÿ‡ธ USA
$10.16 M-99.51%๐Ÿ‡บ๐Ÿ‡ธ USA
$94.31 M-95.47%๐Ÿ‡บ๐Ÿ‡ธ USA